Previous literature indicates anti-tumor effect of Odo A and its derivative, oleandrigenin-3-O-β-D-diginoside, on both HL60 and K562 human leukemia cell lines via activation of the ROS/p53 pathway [12]. The gene discussed is TP53; the disease is neoplasm.